Monthly Archives: April 2012

April 11th Webinar: Expanded Partnering

Join us for Part 3 of the 4 webinar series outlining NEW exhibitor booth partnering, One-on-One System enhancements, and how to get more ROI using partnering at the 2012 BIO International Convention. Unlock the Power of Partnering: Webinar & Discussion on Expanded Partnering and Tips for Partnering Success at BIO Wednesday, April 11th 11:00 am – 12:00 pm ET RSVP Here This partnering webinar will cover the following: New in 2012: Expanded Opportunities with Exhibitor Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

2012 Orphan Disease Forum: Addressing Today’s Opportunities and Challenges

disease

If all of the people with rare disease lived in one country, it would be the world’s third most populous country! Through dedicated companies such as the National Organization for Rare Disorders (NORD) and Centric Health Resources, the pressing issue of orphan diseases and its patients are being addressed. A rare disease is defined by any disease affecting fewer than 200,000 Americans. There are nearly 7,000 such diseases affecting over 350 million people worldwide.  Furthermore, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

2012 MassBioEd Innovative School of the Year – Norton High School

Students

Massachusetts is home to the full ecosystem of life sciences—including our world class academic institutions and medical centers, a vibrant venture capital community, hundreds of biotech companies of all sizes, contract research and manufacturing organizations, and service organizations supporting the industry. It is no wonder then that eleven years ago MassBio established the Massachusetts Biotechnology Foundation to promote biotechnology education and workforce development programs. Each year, the Foundation awards the Innovative School of the Year Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Indices, IPOs, and New Drug Approvals – Update April 3rd 2012

Index-March-20121

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,